Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warby ParkerWRBY -0.19%68 Debt-to-EBITDA is 3.64 as of Jun. 2026, which is 143% above its 10-year median of 1.50. GuruFocus rates WRBY with a GF Score™ of 68/100 and a GF Value™ of $21.61 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Warby Parker ranks worse than 81.36% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Warby Parker's Debt-to-EBITDA or its related term are showing as below:
WRBY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.22 Med: 1.5 Max: 14.31
Current: 4.56
During the past 7 years, the highest Debt-to-EBITDA Ratio of Warby Parker was 14.31. The lowest was -5.22. And the median was 1.50.
WRBY's Debt-to-EBITDA is ranked worse than 81.36% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs WRBY: 4.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Warby Parker Debt-to-EBITDA Related Terms
Warby Parker Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Warby Parker's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WRBY vs XRAY, LMAT, PLSE: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Warby Parker's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Warby Parker Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Warby Parker's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Warby Parker (WRBY) has a Debt-to-EBITDA of 3.64 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Warby Parker. This is 143% above median its historical median of 1.50. According to the industry distribution chart, Warby Parker ranks #384 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 81.4%.
Is Warby Parker's Debt-to-EBITDA too high?
Warby Parker's current Debt-to-EBITDA of 3.64 is 143% above median its 10-year median of 1.50. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Warby Parker's value of 3.64 is 122% above this industry median. Based on the distribution chart, Warby Parker ranks #384 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Warby Parker has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Warby Parker's Debt-to-EBITDA compare to XRAY and LMAT?
According to the Medical Devices & Instruments industry distribution chart, Warby Parker ranks #384 out of 472 companies for Debt-to-EBITDA. This places Warby Parker in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Warby Parker's value of 3.64 is 122% above this benchmark. While the company's 10-year median is 1.50 vs. the industry median of 1.64, Warby Parker has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Warby Parker's current Debt-to-EBITDA of 3.64 is 122% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Warby Parker. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Warby Parker's current Debt-to-EBITDA is 3.64, which is 143% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Warby Parker stock overvalued right now?
Based on GuruFocus' analysis, Warby Parker (WRBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.61, compared to a current price of $26.41 — trading 22.2% above its estimated fair value. The current Debt-to-EBITDA is 3.64, which is 143% above median its 10-year median of 1.50 and 122% above the Medical Devices & Instruments industry median of 1.64. Warby Parker's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Warby Parker (WRBY), the current Debt-to-EBITDA is 3.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Warby Parker (WRBY) Overvalued in 2026?
Based on GuruFocus' analysis, Warby Parker stock appears to be overvalued.
The current stock price of $26.41 is trading 22.2% above its estimated GF Value™ of $21.61.
GuruFocus considers Warby Parker to be Modestly Overvalued.
Key valuation signals for WRBY:
Debt-to-EBITDA: 3.64 (143% above median its 10-year median of 1.50)
GF Value™: $21.61 vs. price of $26.41 (22.2% above fair value)
Industry Position: 122% above the Medical Devices & Instruments median (#384 of 472)
No single metric tells the full story. See the WRBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
68GF Score
Get the complete analysis for WRBY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WRBY has been successfully added to your 
